TY - JOUR
T1 - Central neurotensin inhibits gastric acid secretion
T2 - An adrenergic mechanism in rats
AU - Zhang, Li
AU - Xing, Lianping
AU - Demers, Laurence
AU - Washington, John
AU - Kauffman, Gordon L.
PY - 1989/11
Y1 - 1989/11
N2 - Although parenteral neurotensin (NT) inhibits stimulated gastric acid secretion, published reports on the effect of centrally administered NT on gastric acid secretion are conflicting. This study provides evidence suggesting that, in chronic gastric fistula rats, intracerebroventricularly administered NT (15-60 μg) significantly reduces both basal and pentagastrin-, 2-deoxy-d-glucose-, and carbacol- but not histamine-stimulated gastric acid secretion. Using radioimmunoassay, the concentration of plasma immunoreactive NT increased from 30 to 200 pg/ml at 30 and 60 min, respectively after a single intracerebroventricular (i.c.v.) administration of NT at a dose of 60 μg. These serum NT concentrations can be reproduced by a constant NT i.v. infusion at 2 μg/kg · h. This parenteral infusion dose does not inhibit acid secretion as does i.c.v. NT. Pretreatment with the i.c.v. dopamine-2 receptor antagonists haloperidol or domperidone totally abolishes the inhibitory effect of i.c.v. NT on pentagastrin-stimulated gastric acid secretion. In contrast, pretreatment with the specific dopamine-1 receptor antagonist SCH 23900 or the specific dopamine-2 receptor antagonist sulpiride does not affect i.c.v. NT-induced inhibition of pentagastrin-stimulated gastric acid secretion. Pretreatment (intracerebroventricularly) with the α-adrenergic antagonist phentolamine blocks the antisecretory effect of i.c.v. NT. Administration of 3.0/gmg NT per side directly into nucleus accumbens (NACB), using a stereotaxic technique, significantly reduces basal gastric acid secretion. This effect of central NT is blocked by pretreatment with intra-NACB haloperidol (0.5 μg per side). These findings suggest that NT acts centrally to inhibit gastric acid secretion, an effect that may occur within NACB and be mediated by central nervous system α-adrenergic receptor activation.
AB - Although parenteral neurotensin (NT) inhibits stimulated gastric acid secretion, published reports on the effect of centrally administered NT on gastric acid secretion are conflicting. This study provides evidence suggesting that, in chronic gastric fistula rats, intracerebroventricularly administered NT (15-60 μg) significantly reduces both basal and pentagastrin-, 2-deoxy-d-glucose-, and carbacol- but not histamine-stimulated gastric acid secretion. Using radioimmunoassay, the concentration of plasma immunoreactive NT increased from 30 to 200 pg/ml at 30 and 60 min, respectively after a single intracerebroventricular (i.c.v.) administration of NT at a dose of 60 μg. These serum NT concentrations can be reproduced by a constant NT i.v. infusion at 2 μg/kg · h. This parenteral infusion dose does not inhibit acid secretion as does i.c.v. NT. Pretreatment with the i.c.v. dopamine-2 receptor antagonists haloperidol or domperidone totally abolishes the inhibitory effect of i.c.v. NT on pentagastrin-stimulated gastric acid secretion. In contrast, pretreatment with the specific dopamine-1 receptor antagonist SCH 23900 or the specific dopamine-2 receptor antagonist sulpiride does not affect i.c.v. NT-induced inhibition of pentagastrin-stimulated gastric acid secretion. Pretreatment (intracerebroventricularly) with the α-adrenergic antagonist phentolamine blocks the antisecretory effect of i.c.v. NT. Administration of 3.0/gmg NT per side directly into nucleus accumbens (NACB), using a stereotaxic technique, significantly reduces basal gastric acid secretion. This effect of central NT is blocked by pretreatment with intra-NACB haloperidol (0.5 μg per side). These findings suggest that NT acts centrally to inhibit gastric acid secretion, an effect that may occur within NACB and be mediated by central nervous system α-adrenergic receptor activation.
UR - http://www.scopus.com/inward/record.url?scp=0024457641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024457641&partnerID=8YFLogxK
U2 - 10.1016/0016-5085(89)91682-X
DO - 10.1016/0016-5085(89)91682-X
M3 - Article
C2 - 2551763
AN - SCOPUS:0024457641
SN - 0016-5085
VL - 97
SP - 1130
EP - 1134
JO - Gastroenterology
JF - Gastroenterology
IS - 5
ER -